Open Access

ARTICLE

Zheng Guo¹, Li Xie², Ju Zhao³, Xing Hao³, Xiaotong Hou³, Wei Wang^1,*
Congenital Heart Disease, Vol.19, No.4, pp. 341-350, 2024, DOI:10.32604/chd.2024.057403 - 31 October 2024
Abstract Background: With the decline of birth population and the development of medical technology in China, studies assessing how these changes have affected the adoption of congenital heart disease surgery at the national or regional scale are lacking. Methods: We investigated the status of congenital heart surgery in China in the period from 2017–2022, through investigation of the total rates of cardiac surgeries, cardiopulmonary bypass (CPB), adult congenital heart surgeries (CHS), and pediatric CHS (<18 years old), as recorded by the Extracorporeal Circulation Branch of the Chinese Society of Biomedical Engineering. Subsequently, we evaluated correlations between… More >

View

395

Download

201

Open Access

ARTICLE

Hiroki Nagamine¹, Masaru Miura^1,*, Jun Maeda¹, Takumi Nishiki¹, Maasa Sato², Fumie Takechi³, Shigeru Tateno⁴, Tomoko Ishizu⁵, Yumi Shiina⁶, Ken Kato⁷, Hiroshi Ono⁸, Hiroyuki Yamagishi⁹, Koichiro Niwa⁶
Congenital Heart Disease, Vol.19, No.4, pp. 351-362, 2024, DOI:10.32604/chd.2024.051837 - 31 October 2024
Abstract Background: Aortic root dilatation occurs in adults with tetralogy of Fallot (TOF) after surgical repair, but the longitudinal changes are unclear. The main research aim is to determine the annual dilatation rate of aorta in adults with repaired TOF. Methods: The present, multicentric, prospective cohort study assessed the rate of aortic diameter change in adults aged 20 years or older with TOF, including pulmonary artery atresia, who underwent surgical repair. Clinical data, focusing on echocardiograms, were collected at three-year intervals from seven hospitals. Results: In total, 104 patients (58 males; median age: 29 years) were enrolled.… More >

Graphic Abstract

View

663

Download

237

Open Access

REVIEW

Laura Schianchi^1,*, Fabrizio Vaira², Massimo Chessa^1,3, Serena Francesca Flocco⁴, Arianna Magon⁴, Gianluca Conte⁴, Karina Geraldina Zuniga Olaya⁵, Giacomo Bortolussi⁶, Erika Cioffi¹, Matteo Riccardo Di Nicola², Santo Raffaele Mercuri², Rosario Caruso^4,7
Congenital Heart Disease, Vol.19, No.4, pp. 363-374, 2024, DOI:10.32604/chd.2024.053999 - 31 October 2024
Abstract Background: Hypertrophic scars and keloids, common complications following median sternotomy for cardiac surgery, significantly impact patient quality of life due to their aesthetic and symptomatic burden. Recent advancements in laser therapy have made it a prominent option for managing these complex scars, yet a comprehensive understanding of its efficacy is lacking. The aim of this scoping review is to explore the effects of laser therapy in managing hypertrophic scars and keloids after median sternotomy. Methods: This scoping review analyzed studies up to February 2024 from databases including PubMed, EMBASE, CINAHL, Scopus, Web of Science, and… More >

View

532

Download

213

Open Access

REVIEW

Fajri Marindra Siregar^1,2, Sofia Mubarika Haryana³, Dyah Wulan Anggrahini⁴, Lucia Kris Dinarti⁴, Anggoro Budi Hartopo^4,*
Congenital Heart Disease, Vol.19, No.4, pp. 375-388, 2024, DOI:10.32604/chd.2024.054742 - 31 October 2024
Abstract A particular type of endogenous noncoding RNAs known as circular RNAs (circRNAs) has now become possible biomarkers for several diseases because of their stability and tissue-specific expression patterns. CircRNAs might play a role in various of biological processes. The identification of particular circRNAs dysregulated in pulmonary arterial hypertension (PAH) raises the possibility of these molecules serving as biomarkers for the disease’s early diagnosis and treatment. This review mainly summarizes the role and potential of circRNA as a future biomarker in PAH related to congenital heart disease. This study presented several potential circRNA targets as diagnostic More >

Graphic Abstract

View

380

Download

190

Open Access

ARTICLE

Catalina Vargas-Acevedo¹, Gareth J. Morgan¹, Rhynn Soderstrom², Richard Ing³, Nicholas Houska³, Jenny E. Zablah^1,*
Congenital Heart Disease, Vol.19, No.4, pp. 389-397, 2024, DOI:10.32604/chd.2024.055121 - 31 October 2024
Abstract Introduction: Pulmonary hemorrhage (PHm) is a life-threatening complication that can occur after catheter-based interventions in patients with pulmonary vein stenosis (PVS). Inhaled racemic epinephrine (iRE) and tranexamic acid (iTXA) have been used in other conditions, but a standardized approach in PVS has not been described. We aimed to describe the current management of PHm after PVS catheter-based interventions. Methods: We present a retrospective review of episodes of PHm from July 2022 to February 2024. PHm was defined as frank blood suctioned from the endotracheal tube including blood-tinged secretions and >3% decrease in saturations and/or ventilatory… More >

View

372

Download

187

Open Access

LETTER

Wen Zhang^1,2, Ting Wu^1,2, Xijian Chen^1,3, Hong Luo^1,2,*, Yifei Li^1,4,*
Congenital Heart Disease, Vol.19, No.4, pp. 399-406, 2024, DOI:10.32604/chd.2024.055178 - 31 October 2024
Abstract This article has no abstract. More >

View

385

Download

175

Open Access

REVIEW

Sameh M. Said^1,2,*, Yasin Essa¹
Congenital Heart Disease, Vol.19, No.4, pp. 407-417, 2024, DOI:10.32604/chd.2024.055636 - 31 October 2024
Abstract Minimally invasive approaches for cardiac surgery in children have been lagging in comparison to the adult world. A wide range of the most common congenital heart defects in infants and children can be repaired successfully through a variety of non-sternotomy incisions. This has been shown to be associated with superior cosmetic results, shorter hospital stays, and rapid return to full activity compared to sternotomy. These approaches have been around for decades, but they have not been widely adopted for a variety of reasons. Right axillary thoracotomy is one of these approaches that we believe should More >

View

828

Download

309

Open Access

REVIEW

William H. Marshall V^1,2,*, Lydia K. Wright²
Congenital Heart Disease, Vol.19, No.4, pp. 419-433, 2024, DOI:10.32604/chd.2024.056608 - 31 October 2024
Abstract Heart failure (HF) is common in patients with congenital heart disease (CHD) and there are limited medical therapies. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a proven medical therapy in patients with acquired HF, though data are limited in patients with CHD. The aim of this review is to summarize the current evidence for use of SGLT2i in patients with CHD and identify future directions for study. In available publications, SGLT2i in patients with CHD seem to be well tolerated, with similar side effect profile to patients with acquired HF. Improvement in functional capacity and natriuretic More >

View

544

Download

196